News

Article

Valeant Voluntarily Recalls One Lot of Virazole Due to Sterility Problems

Valeant voluntarily recalled one lot of Virazole due to sterility problems; no adverse events have been reported to date.

 

Valeant Pharmaceuticals issued a voluntary recall on Dec. 30, 2014 for one lot of Virazole (ribavirin powder for solution), 100 mL, 6g vial, 4-pack, lot number 340353F (exp. 10/18), which was distributed to hospitals in the US and Australia. This lot of Virazole, which is used for the treatment of hospitalized infants and young children with severe lower respiratory tract infections due to respiratory syncytial virus, was determined to be non-sterile due to microbial contamination. There have not been any adverse events reported to date.

Any customers with questions regarding the recalled product may contact VPNA at 1.800.321.4576 or by email at pharmcs@valeant.com. Adverse reactions may be reported to VPNA at 877.361.2719 or to FDA’s MedWatch Adverse Event Reporting program online at www.fda.gov/medwatch/report.htm. They may also be reported through a form can be downloaded and filled out at www.fda.gov/MedWatch/getforms.htm or by calling 1.800.332.1088.

Source: FDA

 

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content